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Summary
 
Macrophage inflammatory protein (MIP)-1
 
a
 
, a CC chemokine, enhances proliferation of ma-
ture subsets of myeloid progenitor cells (MPCs), suppresses proliferation of immature MPCs,
and mobilizes mature and immature MPCs to the blood. MIP-1
 
a
 
 binds at least three chemo-
kine receptors. To determine if CCR1 was dominantly mediating the above activities of MIP-1
 
a
 
,
CCR1-deficient (
 
2
 
/
 
2
 
) mice, produced by targeted gene disruption, were used. MIP-1
 
a
 
 en-
hanced colony formation of marrow granulocyte/macrophage colony-forming units (CFU-GM),
responsive to stimulation by granulocyte/macrophage colony-stimulating factor (GM-CSF),
and CFU-M, responsive to stimulation by M-CSF, from littermate control CCR1
 
1
 
/
 
1 
 
but not
CCR1
 
2
 
/
 
2 
 
mice. Moreover, MIP-1
 
a
 
 did not mobilize MPCs to the blood or synergize with
G-CSF in this effect in CCR1
 
2
 
/
 
2
 
 mice. However, CCR1
 
2
 
/
 
2
 
 mice were increased in sensitiv-
ity to MPC mobilizing effects of G-CSF. Multi-growth factor–stimulated MPCs in CCR1
 
2
 
/
 
2
 
and CCR1
 
1
 
/
 
1
 
 marrow were equally sensitive to inhibition by MIP-1
 
a
 
. These results implicate
CCR1 as a dominant receptor for MIP-1
 
a
 
 enhancement of proliferation of lineage-committed
MPCs and for mobilization of MPCs to the blood. CCR1 is not a dominant receptor for
MIP-1
 
a
 
 suppression of MPC proliferation, but it does negatively impact G-CSF–induced
MPC mobilization.
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ature blood cells must be constantly replaced. These
cells are replenished from hematopoietic stem and
progenitor cells (1). Intrinsic to this process is an interacting
network of cytokines that control production and move-
ment of stem and progenitor cells. Identifying the cyto-
kines and specific receptors involved in these processes is
important for clinically modulating blood cell production
and movement.
Macrophage inflammatory protein (MIP)-1
 
a
 
, a cysteine
cysteine (CC) chemokine (2–5), enhances and inhibits pro-
liferation of myeloid progenitor cells (MPCs) and mobilizes
MPCs to the blood. MIP-1
 
a
 
 was first shown to enhance
colony formation of granulocyte/macrophage (CFU-GM)
and macrophage (CFU-M) progenitor cells in vitro (6, 7), a
direct effect on mature subsets of MPCs that responded to
stimulation by GM-CSF or M-CSF. By itself, MIP-1
 
a
 
 did
not stimulate colony formation by any type of MPC. The
enhancing effect of MIP-1
 
a
 
 on lineage-committed cells
was subsequently confirmed by others (8–10). MIP-1
 
a
 
 was
subsequently shown to suppress more immature subsets of
cells, including CFU-spleen (CFU-S [11], considered a stem,
but not long-term marrow repopulating, cell) and imma-
ture MPCs (CFU-GM, erythroid [BFU-E], and multipo-
tential [CFU-GEMM] progenitors) that proliferated in re-
sponse to erythropoietin (Epo), IL-3, GM-CSF, and steel
factor (SLF) (7–10, 12, 13). The suppressive effects were
direct on MPCs (7, 12, 13). MIP-1
 
a
 
 suppression was sub-
stantiated in vivo in mice (8, 14–17) and was confirmed in
patients with breast cancer undergoing a phase I clinical
trial with BB10010 (15), an MIP-1
 
a
 
 analogue. BB10010
was also a modest mobilizing agent for stem and progenitor
cells into the blood of mice (18); BB10010 synergized in
this effect with G-CSF (18), a stem and progenitor cell mo-
bilizer used clinically (1). The MPC mobilizing capacity of
BB10010 was confirmed in a human clinical trial (15).
Chemokines act through seven transmembrane G pro-
tein–linked receptors (2–4). 16 chemokine receptors have
been identified that bind known chemokines, including 9
in the CC chemokine group (2–5). Since MIP-1
 
a
 
 binds
chemokine receptors CCR1, CCR5, and D6, it is not
clear through which chemokine receptor(s) MIP-1
 
a
 
 activ-
ities are mediated. Chemokines do not appear to signal 
1988
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through D6 (19), suggesting that CCR1, CCR5, and/or
an unknown receptor for MIP-1
 
a
 
 may be involved in the
above-noted activities of MIP-1
 
a
 
 on MPCs. CCR1
 
2
 
/
 
2
 
mice have been developed by targeted gene disruption (20),
and have demonstrated certain nonredundant functions in
hematopoiesis, host defense, and inflammation. These mice
were used in this study to demonstrate that CCR1 is a
dominant receptor for enhancement of proliferation of ma-
ture MPCs and mobilization of MPCs to blood, but not for
suppression of proliferation of immature MPCs.
 
Materials and Methods
 
Mice.
 
Generation of CCR1
 
2
 
/
 
2
 
 and littermate control CCR1
 
1
 
/
 
1
 
mice has been described (20). The mice used in this study were
from an F
 
1
 
 or F
 
6
 
 backcross of 129/Sv with C57BL/6 mice. Re-
sults with both were similar and averaged. Age- and weight-
matched CCR1
 
2
 
/
 
2
 
 and CCR1
 
1
 
/
 
1
 
 mice were used. C3H/HeJ
mice were purchased from The Jackson Laboratory.
 
Cytokines.
 
Purified recombinant preparations of cytokines
were used. Human (hu) and murine (mu) MIP-1
 
a
 
, muMIP-2,
and hu preparations of monocyte chemotactic protein (MCP-1),
IL-8, platelet factor 4 (PF4), growth-related oncogene (GRO)-
 
g
 
,
also known as MIP-2
 
b
 
, neutrophil-activating peptide (NAP)-2,
RANTES (regulated upon activation, normal T cell expressed
and secreted), MIP-1
 
b
 
, and muM-CSF were purchased from
R&D Systems. huExodus-1 (21) was a gift from Dr. Robert
Hromas (Indiana University School of Medicine). huENA-78
was a gift from Dr. M.-S. Chang (Amgen Corp., Thousand
Oaks, CA). huIFN-
 
g 
 
inducible protein (IP)-10 was a gift from
Dr. Andreas Sarris (M.D. Anderson Tumor Hospital, Houston,
TX). huGRO-
 
a
 
, muGM-CSF, and muSLF were gifts from Im-
munex Corp. (Seattle, WA). huEpo was purchased from Amgen
Corp. Hemin was purchased from Eastman Kodak Co. PWM
mouse spleen cell–conditioned medium (PWMSCM, a source of
numerous growth factors, including GM-CSF and IL-3) was pre-
pared as described (22).
 
MPC Assays.
 
Colony assays were done as described else-
where (22). Unseparated bone marrow (5 
 
3 
 
10
 
4 
 
cells/ml) and
low-density blood cells (1–2 
 
3
 
 10
 
5 
 
cells/ml, obtained after den-
sity cut procedure) were isolated from mice (22). To assess whether
MIP-1
 
a
 
 stimulates or enhances colony formation, marrow cells
were plated in 0.3% agar (Difco) culture medium in the presence
of 10% FBS (Hyclone, Inc.) with or without muGM-CSF (100
U/ml) or muM-CSF (100 U/ml) and with or without mu or hu-
MIP-1
 
a
 
 (100 ng/ml) (6, 7). Marrow cells were plated in agar
with or without muGM-CSF (100 U/ml) plus muSLF (50 ng/ml)
and with or without chemokines (100 ng/ml each) to evaluate
inhibitory effects on multi-growth factor–stimulated colony for-
mation by CFU-GM (12). Inhibitory assays were also done on
marrow cells growing in 1% methylcellulose culture medium
with 30% FBS, huEpo (1 U/ml), muSLF (50 ng/ml), PWMSCM
(5%), and 0.1 mM hemin for effects on colony formation by
CFU-GM, BFU-E, and CFU-GEMM. Results for CFU-GM
suppression were similar for assays done in agar and methylcellu-
lose and were pooled. Absolute numbers of MPCs in the blood
were calculated based on the number of viable low-density nu-
cleated cells, and the number of colonies was scored per number
of cells plated in methylcellulose culture medium with Epo, SLF,
PWMSCM, and hemin at the above-noted concentrations. The
concentrations of cytokines chosen were predetermined to be
maximally effective. Three plates were scored per point, and col-
 
onies were scored after 7 d incubation in a humidified environ-
ment at 5% CO
 
2
 
 and lowered (5%) O
 
2
 
.
 
In Vivo MPC Mobilization Assay.
 
Mice were given either
control diluent, huG-CSF, huMIP-1
 
a
 
, or G-CSF plus MIP-1
 
a
 
.
Timing and dosages were based on reports by others (18) and our
own preliminary studies. Mice were injected subcutaneously with
either control diluent (pyrogen-free saline; used at the same vol-
ume and timing as for injections of G-CSF plus huMIP-1
 
a
 
),
2.5 
 
m
 
g G-CSF given two times per day for 2 d, or 5 
 
m
 
g MIP-1
 
a
 
administered 12 h after the last injection of either control diluent
or G-CSF. Mice were bled 30 min after injection of MIP-1
 
a
 
 (or
the control diluent for MIP-1
 
a
 
) and then killed.
 
Statistical Analysis.
 
Results are given as mean 
 
6 
 
SEM, and
Student’s 
 
t
 
 test was used to analyze the data.
 
 P 
 
values 
 
, 
 
0.05 des-
ignated significant differences between test points.
 
Results
 
Effects of MIP-
 
a
 
 on Colony Formation by MPCs.
 
To deter-
mine if CCR1 was a dominant receptor for MIP-1
 
a
 
 en-
hancement of colony formation (6, 7), we tested mu and
hu forms of MIP-1
 
a
 
. As shown in Fig. 1, mu and huMIP-
1
 
a
 
 significantly enhanced colony formation by CCR1
 
1
 
/
 
1
 
,
but not by CCR1
 
2
 
/
 
2
 
, marrow cells stimulated to prolifer-
ate by either GM-CSF or M-CSF. Colonies formed in the
presence of GM-CSF, with or without MIP-1
 
a
 
, were
composed mainly of granulocytes and macrophages with
 
,
 
20% of the colonies containing only granulocytes or mac-
rophages. No shifts in colony types were noted in the
absence or presence of MIP-1
 
a
 
. Colonies formed with
M-CSF, with or without MIP-1
 
a
 
, were composed of mac-
rophages. No colonies formed in the absence of GM-CSF
or M-CSF whether or not MIP-1
 
a
 
 was added to the plates.
This suggests that CCR1 acts as a dominant receptor for
the MIP-1
 
a
 
 enhancing effects on MPCs stimulated by
GM-CSF or M-CSF.
MIP-1
 
a
 
 suppresses MPCs stimulated to proliferate by
combinations of growth factors (7, 12, 13). One report
using antibodies to CCR1 suggested that the suppressing
effects of MIP-1
 
a
 
 on colony formation by BFU-E were
mediated by CCR1 (23). To determine if CCR1 was a
dominant receptor for MIP-1
 
a
 
 suppression, we analyzed
the effects of MIP-1
 
a
 
 on colony formation by marrow cells
from CCR1
 
1
 
/
 
1
 
 and CCR1
 
2
 
/
 
2
 
 mice stimulated to prolif-
erate with Epo, PWMSCM, SLF, and hemin. As shown
in Fig. 2, both mu and huMIP-1
 
a
 
 were equally potent in
suppressing colony formation by CFU-GM, BFU-E, and
CFU-GEMM from CCR1
 
1
 
/
 
1
 
 and CCR1
 
2
 
/
 
2
 
 marrow cells.
As controls, other CC (MCP-1 and Exodus-1) and CXC
(IL-8, muMIP-2, ENA-78, IP-10, and PF4) chemokines
known to be inhibitory under these conditions (5) were
tested and found to be equally suppressive on CCR1
 
1
 
/
 
1
 
and CCR1
 
2
 
/
 
2
 
 MPCs (Fig. 2). Chemokines known to be
nonsuppressive (5; GRO-a, GRO-g, NAP-2, RANTES,
and MIP-1b) did not inhibit colony formation of CCR11/1
or CCR12/2 MPCs (Fig. 2). These results suggest that CCR1
is not a dominant receptor for MIP-1a suppression of
multi-growth factor–stimulated MPCs.1989 Broxmeyer et al. Brief Definitive Report
Effects of MIP-1a on Mobilization of MPCs to the Blood in
the Absence or Presence of G-CSF. G-CSF and BB10010, an
MIP-1a analogue, induce mobilization of stem and MPCs
to blood (1, 18) although with different kinetics, and G-CSF
and BB10010 in combination are additive or synergize in
this mobilization (18). In preliminary experiments using
C3H/Hej mice, we confirmed that huMIP-1a induction
of mobilization of MPCs to blood was rapid (within 15 min
to 1 h) and reversible. huRANTES did not have a mobiliz-
ing effect on MPCs in these same experiments. We thus as-
sessed the in vivo MPC mobilizing effects of MIP-1a and
G-CSF. As shown in Fig. 3, MIP-1a and G-CSF each sig-
Figure 1. Effects of mu and huMIP-1a on
colony formation by CFU-GM stimulated
with muGM-CSF and CFU-M stimulated
with muM-CSF from marrow of CCR11/1
compared with CCR12/2 mice. Results
shown are mean percentage of control 6 1
SEM of five separate experiments in which
each experiment used cells pooled from two
to four mice. Control colony numbers for
CCR11/1 and CCR12/2 cells ranged from
25–41 and 26–37, respectively, for CFU-
GM, and 39–66 and 42–61, respectively, for
CFU-M for individual experiments. aP  ,
0.001, significant change from control dilu-
ent, of the indicated mouse strain.
Figure 2. Influence of chemo-
kines on colony formation of
CFU-GM, BFU-E, and CFU-
GEMM from bone marrow
of CCR11/1 compared with
CCR12/2 mice. All chemo-
kines are human unless desig-
nated as murine (mu). Results
shown are percent inhibition 6
1 SEM for two to seven separate
experiments, each using cells
pooled from two to four mice.
Results for mu and huMIP-1a
are from seven (CFU-GM),
three (BFU-E), and three (CFU-
GEMM) experiments. Other re-
sults for CFU-GM are from two
to five experiments and for
BFU-E and CFU-GM from two
experiments. Control colony
numbers for CCR11/1 and
CCR12/2 cells, respectively,
ranged from 55 to 152 and 63 to
145 for CFU-GM, from 18 to
25 and 20 to 24 for BFU-E, and
from 11 to 15 and 12 to 15 for
CFU-GEMM. aP , 0.001, sta-
tistically significant change from
control diluent of a particular
subset of MPCs in either
CCR11/1 or CCR12/2 mice.1990 CCR1 and Myelopoiesis
nificantly mobilized MPCs to the blood of CCR11/1 mice,
and the combination of G-CSF with MIP-1a showed
greater mobilization than either cytokine alone. In contrast,
MIP-1a did not significantly enhance mobilization of
MPCs to the blood of CCR12/2 mice (Fig. 3). Moreover,
MIP-1a did not act with G-CSF to enhance mobilization
further in CCR12/2 mice. However, MPCs in CCR1 2/2
mice were more sensitive to the mobilizing effects of G-CSF
alone than in CCR11/1 mice. In 3 separate experiments in
which 4–5 mice per group per experiment were assessed,
1.3-, 1.7-, and 11.6-fold more CFU-GM, 1.5-, 2.3-, and
4.9-fold more BFU-E, and 2.6- and 3.4-fold more CFU-
GEMM were mobilized in CCR12/2 compared with
CCR11/1 mice. In one experiment, we did not detect
greater mobilization of CFU-GEMM in CCR12/2 mice.
These results suggest that CCR1 is a dominant receptor for
the MPC mobilizing effects of MIP-1a; moreover, CCR1
appears to play a negative role in G-CSF–induced mobili-
zation of MPCs to the blood.
Discussion
Since several chemokine receptors can bind more than
one chemokine and some chemokines can bind more than
one chemokine receptor (2–5), it is not always clear which
chemokine receptor mediates the effects of specific chemo-
kines. MIP-1a binds to three chemokine receptors: CCR1,
CCR5, and D6. Although D6 does not elicit a Ca21 influx
signal in response to MIP-1a or other chemokines that bind
this receptor (19), it is possible that other intracellular signals
are activated through D6 in response to certain chemo-
kines, and there is the possibility that additional receptors will
be identified that bind MIP-1a. The availability of CCR12/2
mice (20) allowed us to assess if CCR1 served as a domi-
nant receptor for three previously reported functions of
MIP-1a. The results presented here clearly demonstrate that
in cells without functional CCR1, MIP-1a did not enhance
proliferation of CFU-GM stimulated by GM-CSF, or
CFU-M stimulated by M-CSF, nor did MIP-1a induce in
vivo mobilization of MPCs to the blood, implicating CCR1
as a dominant receptor for these activities. The MIP-1a–
induced MPC mobilization effects complement our previ-
ous studies in which CCR1 was shown to be a dominant
receptor for bacterial LPS–induced movement of MPCs
between bone marrow, spleen, and blood and for MIP-1a
mobilization of neutrophils to the blood (20).
Our current studies with MIP-1a confirm the mobiliza-
tion effects on MPCs noted by others using an MIP-1a an-
alogue, BB10010 (18), as well as the additive/greater than
additive mobilization apparent when BB10010 is given as a
single injection to mice previously injected with G-CSF.
G-CSF mobilizes stem and progenitor cells for autologous
and allogeneic transplantation (1), and enhancement of this
may be clinically important. We also found that CCR12/2
mice were more sensitive to the MPC mobilizing effects of
G-CSF than were CCR11/1 mice. This unexpected finding
implicates CCR1 as a negative component in G-CSF–
induced MPC mobilization. How CCR1 would negatively
mediate such an effect is not clear. It is known through the
use of G-CSF receptor (G-CSFR)–deficient mice that the
G-CSFR is crucial for G-CSF–induced MPC mobilization
(24). Interestingly, no increase in circulating CFU-GM was
detected in G-CSFR2/2 mice in the absence of added G-CSF
and after administration of IL-8 (24). Thus, CXC chemo-
Figure 3. Mobilization of CFU-GM,
BFU-E, and CFU-GEMM in CCR11/1
compared with CCR12/2 mice after ad-
ministration of G-CSF, huMIP-1a, or
G-CSF plus huMIP-1a. Results are the av-
erage of eight to nine mice, each individu-
ally evaluated, from a total of two complete
experiments. Significant change from con-
trol: aP , 0.001; bP , 0.003; cP , 0.005;
dP , 0.01;  eP , 0.05. Significant change
from G-CSF group: fP , 0.008; gP , 0.05.1991 Broxmeyer et al. Brief Definitive Report
kine receptors have been linked to MPC mobilization by
G-CSF through a G-CSFR.
Although CCR1 has been implicated in MIP-1a sup-
pression of BFU-E proliferation in vitro (23), our studies
suggest that CCR1 is not a dominant receptor for suppres-
sion of MPCs. We have previously shown no significant
difference in cycling of MPCs in CCR12/2 versus
CCR11/1 marrow (20), consistent with CCR1 not being a
dominant receptor for negative regulation of MPC prolif-
eration. This contrasts with studies in other chemokine re-
ceptor–deficient mice. CCR2 binds several chemokines,
including MCP-1 and its murine analogue, JE (25). The
use of CCR22/2 mice demonstrated that CCR2 was a
dominant receptor for suppression of MPCs by MCP-1
and JE (25). The relevance of CCR2 as a receptor involved
in negative regulation of MPCs was confirmed by the fact
that the cycling status of MPCs in CCR22/2 marrow is
greater than that in CCR21/1 marrow (26). IL-8 and
muMIP-2 bind CXCR2, and the use of CXCR22/2 mice
demonstrated that IL-8 and muMIP-2 did not inhibit pro-
liferation of MPCs from CXCR22/2 marrow, and that en-
hanced proliferation of MPCs was apparent in CXCR22/2
compared with CXCR21/1 mice (27).
In conclusion, our data identify CCR1 as the dominant
receptor responsible for MIP-1a enhancement of growth
factor–stimulated MPC proliferation and MIP-1a–induced
MPC mobilization to peripheral blood, but rule out CCR1
as a dominant receptor for negative regulation of hemato-
poiesis by MIP-1a. In addition, the results identify an un-
expected role for CCR1 as a negative regulator of G-CSF–
dependent MPC mobilization to blood. Together with
previous work, our results indicate that CCR1 is a highly
versatile receptor able to mediate a broad range of MIP-1a
actions, including specific steps in MPC proliferation, de-
velopment, and distribution, as well as specific leukocyte
trafficking. Delineation of specific downstream signaling
events will be needed to understand the molecular basis for
these diverse functional responses mediated by MIP-1a ac-
tivation of CCR1.
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